Table 1.
Overview of literature concerning non-cultured cellular grafting in leucoderma
| Author | Evidence level | Follow-up | N | Treatment indication | 0%–24% | Repigmentation achieved in x% |
95%–100% | Repigmentation >75% | Different scores of repigmentation (achieved in 25%–64% 65%–94% x% of patients) Comments | |
|---|---|---|---|---|---|---|---|---|---|---|
| 25%–64% | 65%–94% | |||||||||
| Gauthier, 1992[1] | C | 1–3 months | 12 | FV, ND, SV | 33 | 0 | 42 | 25 | 50 | |
| Olsson, 1998[6] | C | 6–12 months | 26 | CL, GV, HN, ND, P, SV | 8 | 15 | 23 | 54 | 73 | |
| van Geel, 2001[7] | C | 6–20 months | 4 | GV, SV | 0 | 0 | 100 | 0 | 100 | |
| Olsson, 2002[15] | C | 1–7 years | 52* | FV, GV, HN, P, SV | N.R | N.R. | 19** | 21** | N.R. | 0–19 repigmentation:39** 20–64 repigmentation: 21** |
| Issa, 2003[18] | B | 3 months | 11 | GV | N.R. | N.R. | N.R. | N.R. | N.R. | “Significant difference compared to initial area” |
| Mulekar, 2003[19] | C | 1 year | 184 | FV, GV, SV | GV: 23 SV: 4 FV: 26 | GV: 9 SV: 0 FV: 0 | GV: 8 SV: 12 FV: 0 | GV: 53 SV: 84 FV: 69 | N.R. | |
| van Geel, 2004[2] | A2 | 3–12 months | 26 | GV | 57 | 0 | 15 | 27 | 42 | |
| Mulekar, 2004[17] | C | 1–5 years | 64 | FV, SV | SV: 10 FV: 20 | SV:0 FV:7 | SV:6 FV:0 | SV: 84 FV: 73 | N.R. | |
| Mulekar, 2005[20] | C | 1–6 years | 142 | GV | 24 | 9 | 11 | 56 | N.R. | |
| Pandya, 2005[21] | C | 1–6 months | 23 | SV, GV | 11 | 11 | N.R. | N.R. | N.R. | 65–90 repigm.: 18,5 >90 repigm.: 52,2 |
| Xu, 2005[22] | C | 6–18 months | 24 | FV, GV, SV | N.R. | N.R. | N.R. | N.R. | N.R. | 62–93 repigm.: (after 1 treatment): 58 85–97 repigm.: (after 2 treatments): 38 |
| Tegta, 2006[23] | B | 3 months | 20 | FV, GV, SV | Group A: 20# Group B: 70## | N.R. | N.R. | N.R. | Group A: 50 Group B: 0 | 26–50 repigm.: Group A: 10; Group B: 20 51–75 repigm.: Group A: 20; Group B: 10 |
| van Geel, 2006[24] | C | 3–12 months | 39 | FV, GV, SV | 10 | 21 | 43 | 26 | 59 | |
| Mulekar, 2008[11] | B | 4 months | 5 | GV, SV | ReCell: 20 Conv Tx:20 | ReCell: 20 Conv Tx: 20 | ReCell: 20 Conv Tx: 0 | ReCell: 40 Conv Tx: 60 | ReCell: 40 Conv Tx: 60 | |
| Mulekar, 2009[13] | C | 6–12 months | 49 | SV, GV | 18** | 10** | 32** | 40** | N.R. | Treatments on ‘difficult sites’ |
| Back, 2009[14] | A2 | 1 year | 13 | GV § | N.R. | N.R. | N.R. | N.R. | N.R. | No repigm.: 84 Minimal repigm.: 8 Normal to hyperpigm.: 8 |
| Cervelli, 2009[25] | C | 2 years | 15 | FV, GV, SV | 0 | N.R. | N.R. | N.R. | 80 | Recell 25–50 repigm.: 20 |
| Mulekar, 2010[16] | C | 4 years | 25 | FV, SV | FV: 8 SV: 15 | FV: 8 SV: 8 | FV: 8 SV: 15 | FV: 75 SV: 62 | FV: 83 SV: 80 | Only children included |
| Goh, 2010[10] | C | 6 months | 5 | FV, P, SV | 0 | 0 | 100 | 0 | 60 | 6-well plate technique |
| El-Zawahry, 2010[26] | C | 6–17 months | 22 | FV, SV, GV | 27 | 32 | 18 | 23 | 27 | |
| Van Geel, 2010[5] | C | 1–62 months | 82 | GV, SV, HN, P, ND, MV | 12 | 12 | 33 | 43 | 70.7 | |
N = number of patients evaluated; GV, generalized vitiligo; SV, segmental vitiligo; FV, focal vitiligo; MV, mixed vitiligo; UV, unilateral vitiligo; HN, halo nevi; ND, nevus depigmentosus; P, piebaldism; CL, chemical leucoderma; Conv Tx, conventional transplantation; Repigm, repigmentation
*
Number of locations treated
**
percentage repigmentation per treated locations; NR, not reported
#
Threefold of the donor site used
##
Fivefold of the donor site used
§
In 69% active disease